Frontiers in Oncology (Aug 2022)

Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy

  • Yuheng Zou,
  • Hongying Zhang,
  • Feng Bi,
  • Qiulin Tang,
  • Huanji Xu

DOI
https://doi.org/10.3389/fonc.2022.938502
Journal volume & issue
Vol. 12

Abstract

Read online

Cholesterol metabolism is often dysregulated in cancer. Squalene monooxygenase (SQLE) is the second rate-limiting enzyme involved in cholesterol synthesis. Since the discovery of SQLE dysregulation in cancer, compelling evidence has indicated that SQLE plays a vital role in cancer initiation and progression and is a promising therapeutic target for cancer treatment. In this review, we provide an overview of the role and regulation of SQLE in cancer and summarize the updates of antitumor therapy targeting SQLE.

Keywords